Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Patent metadata

Field	Value
Publication number	US-9890377-B2
Application number	US-201313889512-A
Country	US
Kind code	B2
Filing date	May 8, 2013
Priority date	Apr 11, 2008
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

First claim

The invention claimed is:

1. A method of removing an antigen from plasma, the method comprising:
(a) identifying an individual in need of having an antigen removed from the individual's plasma;
(b) providing an antibody that binds to the antigen through the antigen-binding domain of the antibody and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 2 to 10,000, when KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10mM MES buffer, 0.05% polyoxyethylenesorbitan monolaurate, and 150mM NaCl at 37° C.; and
(c) administering the antibody to the individual, wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a human IgG or a humanized IgG.

2. The method of claim 1 , comprising determining the level of the antigen in the individual's plasma before and after administration of the antibody.

3. The method of claim 1 , comprising confirming that the level of the antigen in the individual's plasma is decreased following administration of the antibody.

4. The method of claim 1 , wherein the antigen is a soluble antigen.

5. The method of claim 1 , wherein the antigen is membrane-bound.

6. The method of claim 1 , wherein the antigen is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-31, IL-23, IL-2 receptor, IL-6 receptor, OSM receptor, gp130, IL-5 receptor, CD40, CD4, Fas, osteopontin, CRTH2, CD26, PDGF-D, CD20, monocyte chemotactic factor, CD23, TNF-α, HMGB-1, α4 integrin, ICAM-1, CCR2, CD11a, CD3,IFNγ, BLyS, HLA-DR, TGF-β, CD52, and IL-31 receptor.

7. The method of claim 1 , wherein the KD(pH5.8)/KD(pH7.4) value is 10 or higher.

8. The method of claim 1 , wherein the KD(pH5.8)/KD(pH7.4) value is 30 or higher.

9. The method of claim 1 , wherein the KD(pH5.8)/KD(pH7.4) value is 40 or higher.

10. The method of claim 1 , further comprising determining the KD(pH5.8)/KD(pH7.4) value of the antibody.

11. A method of removing an antigen from plasma in a subject, the method comprising:
(a) identifying a first antibody that binds to the antigen through the antigen-binding domain of the first antibody;
(b) identifying a second antibody that:
(1) binds to the antigen through the antigen-binding domain of the second antibody,
(2) is identical in amino acid sequence to the first antibody except having at least one amino acid of a variable region of the first antibody substituted with histidine and/or at least one histidine inserted into a variable region of the first antibody,
(3) has a KD(pH5.8)/KD(pH7.4) value that is higher than the first antibody's KD(pH5.8)/KD(pH7.4) value, and is between 2 and 10,000, wherein KD(pH5.8)/KD(pH7.4) is defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4 when KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10mM MES buffer, 0.05% polyoxyethylenesorbitan monolaurate, and 150mM NaCl at 37° C.,
(4) binds to the antigen in plasma in vivo,
(5) dissociates from the bound antigen under conditions present in an endosome in vivo, and
(6) is a human IgG or a humanized IgG;

(c) identifying a subject in need of having his or her plasma level of the antigen reduced; and
(d) administering the second antibody to the subject so that the plasma level of the antigen in the subject is reduced.

12. The method of claim 11 , wherein the second antibody is more effective at reducing levels of the antigen in plasma of humans than is the first antibody.

13. The method of claim 11 , wherein the antigen is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-31, IL-23, IL-2 receptor, IL-6 receptor, OSM receptor, gp130, IL-5 receptor, CD40, CD4, Fas, osteopontin, CRTH2, CD26,PDGF-D, CD20, monocyte chemotactic factor, CD23, TNF-α, HMGB-1, α 4 integrin, ICAM-1, CCR2, CD11a, CD3,IFNγ, BLyS, HLA-DR, TGF-β, CD52,and IL-31 receptor.

14. The method of claim 11 , wherein the second antibody's KD(pH5.8)/KD(pH7.4) value is 10 or higher.

15. The method of claim 11 , wherein the second antibody's KD(pH5.8)/KD(pH7.4) value is 30 or higher.

16. The method of claim 11 , wherein the second antibody's KD(pH5.8)/KD(pH7.4) value is 40 or higher.

17. The method of claim 11 , further comprising determining the KD(pH5.8)/KD(pH7.4) value of the second antibody.

18. A method of removing an antigen from plasma in a subject, the method comprising:
(a) identifying a first antibody that:
(1) binds to the antigen through the antigen-binding domain of the first antibody,
(2) is identical in amino acid sequence to a second antibody that binds to the antigen through the antigen-binding domain of the second antibody, except that at least one variable region of the first antibody has at least one more histidine residue than does the corresponding variable region of the second antibody,
(3) has a KD(pH5.8)/KD(pH7.4) value that is higher than the second antibody's KD(pH 5 .8)/KD(pH7.4) value, and is between 2 and 10,000, wherein KD(pH5.8)/KD(pH7.4) is defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4 when KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10mM MES buffer, 0.05% polyoxyethylenesorbitan monolaurate, and 150mM NaCl at 37° C.,
(4) binds to the antigen in plasma in vivo,
(5) dissociates from the bound antigen under conditions present in an endosome in vivo, and
(6) is a human IgG or a humanized IgG;

(b) identifying a subject in need of having his or her plasma level of the antigen reduced; and
(c) administering the first antibody at least once to the subject so that the plasma level of the antigen in the subject is reduced.

19. The method of claim 18 , comprising determining the subject's plasma level of the antigen both before the first antibody is administered to the subject and after the first antibody is administered at least once to the subject, and determining that the level of the antigen is lower after administration of the first antibody.

20. The method of claim 18 , wherein the antigen is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-31, IL-23, IL-2 receptor, IL-6 receptor, OSM receptor, gp130, IL-5 receptor, CD40, CD4, Fas, osteopontin, CRTH2, CD26, PDGF-D, CD20, monocyte chemotactic factor, CD23, TNF-α, HMGB- 1 , α4 integrin, ICAM-1, CCR2, CD11a, CD3, IFNγ, BLyS, HLA-DR, TGF-β, CD52, and IL-31 receptor.

21. The method of claim 18 , wherein the first antibody's KD(pH5.8)/KD(pH7.4) value is 10 or higher.

22. The method of claim 18 , wherein the first antibody's KD(pH5.8)/KD(pH7.4) value is 30 or higher.

23. The method of claim 18 , wherein the first antibody's KD(pH5.8)/KD(pH7.4) value is 40 or higher.

24. The method of claim 18 , further comprising determining the KD(pH5.8)/KD(pH7.4) value of the first antibody.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Igawa Tomoyuki
• Ishii Shinya
• Maeda Atsuhiko
• Nakai Takashi

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title